Murine B-cell leukemia lymphoma (BCL1) cells as a target for NK cell-mediated immunotherapy

L. Weiss, S. Reich, O. Mandelboim, S. Slavin*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Natural killer (NK) cells are important for their ability to recognize and lyse tumor cells and virus infected cells. NK cells express triggering receptors that are specific for non-MHC ligands. This article describes the 35S release cytotoxic assay, which measures the ability of NK cells derived from spleen cells taken from polyIC-treated mice to lyse B-cell leukemia (BCL1) cells. BCL1 cells express ligands for NKp46 on the cell surface membrane and they are sensitive to allogeneic but not syngeneic IL-2 activated natural killer cells.

Original languageAmerican English
Pages (from-to)1137-1141
Number of pages5
JournalBone Marrow Transplantation
Issue number11
StatePublished - 1 Jun 2004

Bibliographical note

Funding Information:
We thank the Danny Cunniff Leukemia Research Laboratory; the Gabrielle Rich Leukemia Research Foundation; the Cancer Treatment Research Foundation; the Novotny Trust and the Fig Tree Foundation for their continuous support of our ongoing basic and clinical research.


  • B-cell leukemia (BCL)
  • Immunity
  • Lymphokine activated killer cells (LAK cells)
  • Murine


Dive into the research topics of 'Murine B-cell leukemia lymphoma (BCL1) cells as a target for NK cell-mediated immunotherapy'. Together they form a unique fingerprint.

Cite this